ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
May 26, 2022 09:25 ET
|
The Rosen Law Firm PA
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December...
DEADLINE ALERT for FHS, OSCR, UPST, AXSM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
May 25, 2022 12:00 ET
|
Law Offices of Howard G. Smith
BENSALEM, Pa., May 25, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
May 20, 2022 13:53 ET
|
The Rosen Law Firm PA
NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Axsome...
DEADLINE ALERT for FHS, OSCR, UPST, and AXSM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
May 20, 2022 11:45 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, May 20, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded...
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Axsome Therapeutics, Inc. (NASDAQ: AXSM)
May 17, 2022 01:45 ET
|
Bernstein Liebhard LLP
Did you lose money on investments in Axsome Therapeutics? If so, please visit Axsome Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
March 28, 2022 06:00 ET
|
Axsome Therapeutics, Inc.
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated...
Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum
March 11, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
March 02, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
February 15, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...